Cantor Fitzgerald set a $17.00 price objective on Teva Pharmaceutical Industries Limited (NYSE:TEVA) in a report released on Monday morning. The firm currently has a hold rating on the stock.

Several other analysts also recently weighed in on TEVA. BidaskClub upgraded Teva Pharmaceutical Industries Limited from a hold rating to a buy rating in a research note on Wednesday, July 5th. Oppenheimer Holdings, Inc. set a $41.00 price target on Teva Pharmaceutical Industries Limited and gave the stock a buy rating in a research note on Tuesday, June 27th. Royal Bank Of Canada set a $38.00 price target on Teva Pharmaceutical Industries Limited and gave the stock a buy rating in a research note on Friday, June 16th. Mizuho raised Teva Pharmaceutical Industries Limited from a neutral rating to a buy rating and increased their price target for the company from $25.00 to $30.00 in a report on Thursday, June 15th. Finally, Vetr downgraded Teva Pharmaceutical Industries Limited from a strong-buy rating to a buy rating and set a $32.04 price target for the company. in a report on Monday, June 5th. Five analysts have rated the stock with a sell rating, eighteen have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of Hold and an average price target of $30.91.

Shares of Teva Pharmaceutical Industries Limited (TEVA) opened at 18.47 on Monday. Teva Pharmaceutical Industries Limited has a 52-week low of $15.22 and a 52-week high of $46.09. The stock’s market capitalization is $18.77 billion. The stock’s 50 day moving average is $17.00 and its 200 day moving average is $27.16.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the consensus estimate of $1.06 by ($0.07). The company had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The business’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.25 earnings per share. Equities research analysts expect that Teva Pharmaceutical Industries Limited will post $4.31 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was first published by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.watchlistnews.com/teva-pharmaceutical-industries-limited-teva-given-a-17-00-price-target-at-cantor-fitzgerald/1604816.html.

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th were given a dividend of $0.085 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $0.34 dividend on an annualized basis and a yield of 1.84%. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is presently -15.36%.

Several institutional investors and hedge funds have recently modified their holdings of TEVA. Perpetual Ltd bought a new stake in shares of Teva Pharmaceutical Industries Limited during the second quarter valued at about $2,865,000. WFG Advisors LP lifted its holdings in Teva Pharmaceutical Industries Limited by 2,650.1% in the second quarter. WFG Advisors LP now owns 29,784 shares of the company’s stock worth $989,000 after purchasing an additional 28,701 shares during the period. Oak Associates Ltd. OH lifted its holdings in Teva Pharmaceutical Industries Limited by 0.6% in the second quarter. Oak Associates Ltd. OH now owns 379,924 shares of the company’s stock worth $12,621,000 after purchasing an additional 2,114 shares during the period. Cetera Investment Advisers acquired a new stake in Teva Pharmaceutical Industries Limited in the second quarter worth about $373,000. Finally, Sterneck Capital Management LLC lifted its holdings in Teva Pharmaceutical Industries Limited by 5.4% in the second quarter. Sterneck Capital Management LLC now owns 131,907 shares of the company’s stock worth $4,382,000 after purchasing an additional 6,702 shares during the period. 56.77% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.